Abstract
Purpose. The purpose of these studies were to determine the distribution of a lipophilic antineoplastic agent, annamycin (Ann), and its liposomal counterpart (LAnn) in plasma which had been altered in its lipoprotein concentration and lipid composition.
Methods. Ann, LAnn, and doxorubicin (a hydrophilic control) were incubated in human plasma for 1 hour at 37°C. Following incubation plasma samples were assayed by fluorimetry for drug in each of the lipoprotein and lipoprotein-deficient plasma (LPDP) fractions. To assess the influence of modified lipoprotein concentrations and lipid composition on plasma distribution of Ann and LAnn, either Ann or LAnn were incubated in human plasma which had been supplemented with very low density lipoproteins (VLDL) or low density lipoproteins (LDL).
Results. When unbound Ann or doxorubicin was incubated in plasma for 1 hour at 37°C, the majority of drug was found in the LPDP fraction. However, when Ann was incorporated into liposomes composed of dimyristoylphosphatidylcholine and dimyristoylphosphatidylglycerol (LAnn) the majority of Ann was recovered in the high-density lipoprotein (HDL) fraction. Elevation of plasma LDL-cholesterol or VLDL-triglyceride concentrations increased the amounts of Ann and LAnn associated with these lipoprotein classes. Alterations in HDL composition decreased the amount of Ann, but increased the amount of L-Ann within the HDL fraction. Lipid transfer protein (LTP) activity did not significantly modify the plasma distribution of Ann and LAnn in short-term experiments, but the modified lipoprotein composition that LTP facilitates in long-term incubations reduced the capacity of VLDL and LDL to accept drug.
Conclusions. These findings suggest that lipoprotein concentration and composition alter the plasma distribution of Ann and LAnn and may help to explain the discrepancies observed in the pharmacokinetics of Ann and LAnn when they are administered to healthy versus cancer patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
R. Weiss, G. Sarosy, K. Clagett-Carr, M. Russo, and B. Leyland-Jones. Anthracycline analogs: the past, present, and future. Cancer Chemother. Pharmacol. 18:185–197 (1986).
L. Lanaz and J. A. Page. Cardiotoxicity of Adriamycin and related anthracyclines. Cancer Treat. Rev. 3:111–120 (1976).
H. M. Coley, P. R. Twentyman, and P. Workman. 9-Alkyl, morpholinyl anthracyclines in the circumvention of multidrug resistance. Eur. J. Cancer. 6:665–667 (1990).
P Ahlgren, L. Panasci, J. Shelton, P. Gruner, D. Major, B. Leyland-Jones, S. Saletan, F. Pilkiewicz, and L. Haccoun. Phase II study of liposomal doxorubicin (TLCD99) in metastatic breast cancer. Proc ASCO 11:82–88 (1992).
A. Rahman, D. Carmichael, M. Harris, J. K. Roh. Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res. 46:2295–2300 (1986).
S. Oudard, A. Thierry, T. J. Jorgensen, and A. Rahman. Sensitization of multidrug-resistant colon cancer cells to doxorubicin encapsulated in liposomes. Cancer Chemother. Pharmacol. 28:259–262 (1991).
R. Perez-Soler and W. Priebe. Anthracycline antibiotic with high liposome entrapment structural features and biological activity. Cancer Res. 50:4260–4266 (1990).
Y. Ling, W. Priebe, L. Y. Yang, T. G. Burke, Y. Pommier, and R. Perez-Soler. In vitro cytotoxicity, cellular pharmacology, and DNA lesions induced by Annamycin, an Anthracycline Derivative with High Affinity for Lipid Membranes. Cancer Res. 53:1583–1589 (1993).
Y. Zou, W. Priebe, Y. Ling, and R. Perez-Soler. Organ distribution and tumor uptake of annamycin a new anthracycline derivative with high affinity for lipid membranes, entrapped in multilamellar vesicles. Cancer Chemother. Pharmacol. 32:190–196 (1993).
K. M. Wasan, K. Vadiei, G. Lopez-Berestein, and D. R. Luke. Pharmacokinetics, tissue distribution and toxicity of free and liposomal amphotericin B in a diabetic rat model. J. Infect. Dis. 161:562–566 (1990).
K. M. Wasan, V. B. Grossie, Jr., and G. Lopez-Berestein. Concentrations in serum and distribution in tissue of free and liposomal amphotericin B in rats during continuous Intralipid Infusion. Antimicrobial Agents Chemother. 38:2224–2226 (1994).
K. M. Wasan, G. A. Brazeau, A. Keyhani, A. C. Hayman, and G. Lopez-Berestein. Role of liposome composition and temperature on the distribution of amphotericin B in serum lipoproteins. Antimicrob. Agents Chemother. 37:246–250 (1993).
K. M. Wasan, R. E. Morton, M. G. Rosenblum, and G. Lopez-Berestein. Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: Role of Lipid Transfer Protein. J. Pharm. Sci. 83:1006–1010 (1994).
G. L. Peterson. A simplication of the protein assay method of Lowery et al. which is more generally applicable. Anal. Biochem. 83:346–356 (1977).
M. Burstein, H. R. Scholnick, and R. Morfin. Rapid method for the isolation of lipoproteins from human serum by precipitation with polyanions. J. Lipid Res. 11:583–595 (1970).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wasan, K.M., Morton, R.E. Differences in Lipoprotein Concentration and Composition Modify the Plasma Distribution of Free and Liposomal Annamycin. Pharm Res 13, 462–468 (1996). https://doi.org/10.1023/A:1016065114515
Issue Date:
DOI: https://doi.org/10.1023/A:1016065114515